ORTIN GLOBAL financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹0.0cr−70.9% on Q1 FY26
Net profit
−₹0.3cr−₹0.2 cr in Q1 FY26
EBITDA margin
−2,919.8%−2408.3 pts on Q1 FY26
EPS
−₹0.42−₹0.22 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue0.00.0−70.9%
EBITDA−0.3−0.2—
EBITDA margin−2,919.8%−511.6%−2408.3 pts
Profit before tax−0.3−0.2—
Net profit−0.3−0.2—
EPS−₹0.42−₹0.22—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹0.0 crNet profit₹−0.3 crNet margin−2,912.9%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
10.1————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.60.60.40.50.2
1.01.00.31.86.4
10.5————
0.10.10.32.16.0
—−70.6%−83.8%−64.9%—
−1.2−1.0−0.9−6.50.5
−1,618.7%−1,030.1%−258.2%−309.6%8.7%
−1.2−1.0−0.9−6.80.3
−0.9−0.7−0.8−8.0−0.1
−1,248.8%−736.7%−247.3%−380.8%−1.1%
−₹1.11−₹0.91−₹1.04−₹9.89−₹0.08
—+12.5%+89.5%−11,919.4%—
—−0.6−0.4−3.7−0.2
—0.0−0.00.0−0.0
−0.6−0.6−0.4−3.7−0.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ORTINGLOBE₹12.41

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹10.1 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————10.1
- Cash, Equiv & ST Investments0.20.50.40.60.6
+ Total Debt6.41.80.31.01.0
Enterprise Value————10.5
Revenue6.02.10.30.10.1
Growth %, YoY—-64.9-83.8-70.6—
EBITDA0.5-6.5-0.9-1.0-1.2
Margin %8.65-309.60-258.21-1,030.05-1,618.67
EBIT0.3-6.8-0.9-1.0-1.2
Net Income-0.1-8.0-0.8-0.7-0.9
Margin %-1.11-380.82-247.34-736.72-1,248.82
EPS, Adj (current shares)-0.08-9.89-1.04-0.91-1.11
Growth %, YoY—-11,919.4+89.5+12.5—
Cash from Operations-0.2-3.7-0.4-0.6—
Capital Expenditures-0.0-0.0-0.0-0.0—
Free Cash Flow-0.2-3.7-0.4-0.6-0.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

ORTIN GLOBAL financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

ORTIN GLOBAL (NSE: ORTINGLOBE) had a market capitalisation of ₹10.7 crore at the 29 October 2026 close (₹13.13 a share) and a price-to-book ratio of 8.63. In FY26 its consolidated net loss was ₹74 lakh on revenue of ₹10 lakh; in Q1 FY27 (April–June 2026) it was a loss of ₹34 lakh. Its debt-to-equity ratio was 0.81 on 31 March 2026. Promoters held 1.24% of the shares on 30 September 2026.

ORTIN GLOBAL Q1 FY27 results
filed 14 August 2026
Share price used
₹13.13 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

ORTIN GLOBAL at a glance · consolidated

Market cap
₹10.7 Crat ₹13.13 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
8.63book value ₹1.52 a share
ROE (FY26)
−46.1%−10.8 pts vs FY25ROCE −46.3%
Debt to equity
0.81net debt ₹40 lakh
Promoter holding
1.24%unchanged vs 30 Jun 202630 September 2026
Net worth
₹1.2 Cr−37.4% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹56 lakh
EPS (FY26)
−₹0.91

Questions

What is the ORTIN GLOBAL PE ratio today?

ORTIN GLOBAL's PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹90 lakh, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹10.7 crore at ₹13.13 a share.

What is the ORTIN GLOBAL PB ratio (price to book value)?

ORTIN GLOBAL's price-to-book (PB) ratio is 8.63 at the 29 October 2026 close: a market capitalisation of ₹10.7 crore divided by shareholders' equity (book value) of ₹1.2 crore on 31 March 2026. That is a book value of ₹1.52 per share against a share price of ₹13.13.

What is the ORTIN GLOBAL net worth?

ORTIN GLOBAL's net worth — shareholders' equity in its consolidated balance sheet — was ₹1.2 crore on 31 March 2026, down 37.4% from ₹2 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹10.7 crore at the 29 October 2026 close.

What is the ORTIN GLOBAL market cap?

ORTIN GLOBAL's market capitalisation was ₹10.7 crore at the 29 October 2026 close: 81.31 lakh shares at ₹13.13 each.

Is ORTIN GLOBAL debt free?

No. ORTIN GLOBAL had borrowings of ₹1 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.81. Its cash and current investments were ₹61 lakh, so its net debt was ₹40 lakh.

What is the ORTIN GLOBAL EPS?

ORTIN GLOBAL's basic earnings per share (EPS) were −₹0.91 in FY26, against −₹1.04 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹1.12.

What is the ORTIN GLOBAL debt to equity ratio?

ORTIN GLOBAL's debt-to-equity ratio was 0.81 on 31 March 2026: borrowings of ₹1 crore against total equity of ₹1.2 crore. A year earlier, on 31 March 2025, it was 0.13.

What is the ORTIN GLOBAL free cash flow?

In FY26, ORTIN GLOBAL generated ₹56 lakh of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹56 lakh. In FY25 it was −₹41 lakh.

When are the ORTIN GLOBAL next results?

ORTIN GLOBAL has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the ORTIN GLOBAL ROE and ROCE?

In FY26, ORTIN GLOBAL's return on equity (ROE) was −46.1% and its return on capital employed (ROCE) was −46.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −35.3% and ROCE −26.4%.

What are the ORTIN GLOBAL latest quarterly results?

ORTIN GLOBAL's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net loss ₹34 lakh, wider than the loss of ₹18 lakh in Q1 FY26; revenue from operations ₹1.2 lakh, down 70.9% year on year.

ORTIN GLOBAL vs Lasa Supergenerics: how do they compare?

In FY26, ORTIN GLOBAL earned net profit of ₹74 lakh on revenue of ₹10 lakh, against ₹34.1 crore on ₹25.1 crore for Lasa Supergenerics. ORTIN GLOBAL's operating margin was −1,030.6% (Lasa Supergenerics −136.9%) and its return on equity −46.1% (Lasa Supergenerics −51.1%).

What is the ORTIN GLOBAL book value per share?

ORTIN GLOBAL's book value per share was ₹1.52 on 31 March 2026: shareholders' equity of ₹1.2 crore divided by the 81.31 lakh shares in issue, down 37.4% from ₹2.43 a year earlier. The share price at the 29 October 2026 close was ₹13.13.

What is the ORTIN GLOBAL promoter holding?

Promoters held 1.24% of ORTIN GLOBAL on 30 September 2026, up 0.01 percentage points from 1.23% the previous quarter and up 0.01 percentage points from 1.23% a year earlier, according to the shareholding pattern filed with NSE.

What is the ORTIN GLOBAL shareholding pattern?

On 30 September 2026, ORTIN GLOBAL's shares were held by promoters 1.24%, foreign portfolio investors (FII/FPI) 0.67% and retail and other non-institutional investors 98.09%. Over the year, FII holding was down 1.01 percentage points from 1.68%.

What is the ORTIN GLOBAL revenue and profit in FY26?

In FY26 (April 2025–March 2026), ORTIN GLOBAL's consolidated net loss was ₹74 lakh, narrower than the loss of ₹85 lakh in FY25, on revenue from operations of ₹10 lakh (down 70.6%).

How does ORTIN GLOBAL compare with its peers?

On FY26 consolidated figures, against Lasa Supergenerics, Mangalam Drugs And Organics and Biofil Chemicals & Pharmaceuticals: ORTIN GLOBAL's operating margin of −1,030.6% is the lowest of the four (Lasa Supergenerics −136.9%, Mangalam Drugs And Organics −14.3%, Biofil Chemicals & Pharmaceuticals 1.3%; peer average −49.9%); its return on equity of −46.1% is the third highest of the four (Lasa Supergenerics −51.1%, Mangalam Drugs And Organics −35.2%, Biofil Chemicals & Pharmaceuticals 13.8%; peer average −24.2%).

Where do these ORTIN GLOBAL figures come from?

From ORTIN GLOBAL's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.